Movano Inc. (Move): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage rapide de la technologie de la santé en évolution, Movano Inc. (Move) émerge comme un innovateur révolutionnaire, transformant la surveillance de la santé des femmes grâce à des dispositifs portables propulsés par l'IA de pointe. En mélangeant de manière transparente la technologie des capteurs avancés, des informations sur la santé personnalisées et une précision de qualité médicale approuvée par la FDA, Movano redéfinit la façon dont les femmes suivent, comprennent et gèrent de manière proactive leur santé. Leur modèle commercial unique représente une approche stratégique pour autonomiser les personnes ayant un suivi de santé continu et non invasif qui va au-delà des solutions de bien-être traditionnelles.

Movano Inc. (Move) - Modèle d'entreprise: partenariats clés

Collaborations stratégiques avec les entreprises de technologie de santé

Movano Inc. a établi des partenariats avec les sociétés de technologie de santé suivantes:

Entreprise partenaire	Focus de la collaboration	Année initiée
Qualcomm Life	Solutions de connectivité sans fil	2022
Texas Instruments	Intégration de la technologie des semi-conducteurs	2023

Partenariats avec les fabricants d'appareils médicaux

Les partenariats de fabrication de dispositifs médicaux de Movano comprennent:

• Flex Ltd. - Support manufacturier pour la production de RONANO RING
• Sanmina Corporation - Advanced Electronics Manufacturing Services

Alliances potentielles avec les fournisseurs d'assurance maladie

Engagements actuels d'assurance maladie:

Assureur	Portée du partenariat potentiel	Statut
UnitedHealthcare	Intégration de surveillance de la santé à distance	Discussions exploratoires
Cigna	Analyse des données du programme de bien-être	Négociations préliminaires

Relations collaboratives avec les organisations de recherche clinique

Détails de la collaboration de recherche:

• Centre médical de l'Université de Stanford - Recherche en santé des femmes
• Mayo Clinic - Études de surveillance des maladies chroniques
• Cleveland Clinic - Validation clinique de la technologie portable

Investissements totaux de collaboration de recherche: 1,2 million de dollars en 2023

Movano Inc. (Move) - Modèle d'entreprise: activités clés

Développement d'appareils portables de surveillance de la santé alimentée par l'IA

Movano Inc. a investi 12,4 millions de dollars en R&D pour le développement de la technologie portable en 2023. La société se concentre sur la création de dispositifs de surveillance de la santé axés sur l'IA ciblant spécifiquement le suivi de la santé des femmes.

Catégorie d'appareil	Budget de développement	Achèvement prévu
RINE SMART RINIAN	5,2 millions de dollars	Q2 2024
Health des femmes portable	4,8 millions de dollars	Q3 2024

Validation clinique des technologies de suivi de la santé

Movano a mené 3 études cliniques en 2023 pour valider les technologies de surveillance de la santé, avec un investissement total de recherche de 3,6 millions de dollars.

• Validation de la précision de la surveillance de la santé des femmes
• Étude de précision de suivi de la fréquence cardiaque continue
• Vérification de la mesure du niveau de l'oxygène sanguin

Recherche et développement des technologies de capteurs avancés

La société a alloué 7,9 millions de dollars à la recherche avancée en technologie des capteurs en 2023.

Technologie des capteurs	Investissement en R&D	Focus technologique
Capteurs biométriques	3,1 millions de dollars	Surveillance continue de la santé
Suivi amélioré AI	2,5 millions de dollars	Insistance à la santé prédictive

Compliance réglementaire et processus de dégagement de la FDA

Movano a dépensé 2,1 millions de dollars pour la conformité réglementaire et les efforts de dédouanement de la FDA en 2023.

• FDA 510 (k) Débarquant de la notification pré-market
• Conformité de la classification des dispositifs médicaux
• Gestion continue de la documentation réglementaire

Movano Inc. (Move) - Modèle d'entreprise: Ressources clés

Technologie des capteurs de surveillance de la santé propriétaire

Movano Inc. a développé un Technologie de détection de la radiofréquence (RF) pour le suivi de la santé. Au quatrième trimestre 2023, la société détenait 12 brevets délivrés liés à cette technologie.

Spécifications technologiques	Détails techniques
Précision du capteur	± 3% pour la surveillance de la fréquence cardiaque
Gamme de fréquences	2,4 GHz à 5,8 GHz
Consommation d'énergie	Moins de 50 MW

Équipes d'ingénierie et de recherche médicale qualifiées

En janvier 2024, Movano Inc. a employé 47 employés à temps plein d'horizons spécialisés.

• Personnel d'ingénierie: 28 employés
• Équipe de recherche médicale: 12 chercheurs
• Spécialistes de la science des données: 7 professionnels

Propriété intellectuelle et portefeuille de brevets

Movano Inc. maintient une solide stratégie de propriété intellectuelle.

Catégorie de brevet	Nombre de brevets
Brevets délivrés	12
Demandes de brevet en instance	8
Brevets provisoires	5

Capacités avancées des logiciels et des données

La société a développé des algorithmes logiciels propriétaires pour l'interprétation des données de santé.

• Modèles d'apprentissage automatique: 4 algorithmes de base
• Vitesse de traitement des données: 500 points de données par seconde
• Capacité de stockage cloud: 250 To

Movano Inc. (Move) - Modèle d'entreprise: Propositions de valeur

Surveillance continue de la santé continue non invasive pour les femmes

Movano Ring génère des données de santé en temps réel grâce à une surveillance continue, ciblant les besoins de suivi de la santé des femmes.

Surveillance des mesures	Niveau de précision
Rythme cardiaque	± 2 bpm précision
Niveaux d'oxygène sanguin	Précision de 95 à 99%
Température corporelle	± 0,5 ° F

Advanced Health Insights grâce à la technologie portable

La technologie propriétaire de Movano offre une analyse de santé complète.

• Technologie des capteurs de qualité médicale approuvée par la FDA
• Traitement des données de santé en temps réel
• Informations sur l'apprentissage automatique

Suivi de santé personnalisé et analyse prédictive

Fonctionnalité de suivi de la santé	Points de données collectés
Suivi du cycle menstruel	18 paramètres physiologiques
Analyse du sommeil	7 mesures de stade de sommeil
Surveillance des activités	12 Classifications de mouvement

Appareils portables de qualité médicale approuvés de la FDA

Movano Ring représente un dispositif portable de qualité médicale avec conformité réglementaire.

• Première bague intelligente approuvée par la FDA pour une surveillance continue de la santé
• Classification des dispositifs médicaux de classe II
• Gestion des données conformes à la HIPAA

Spécification de l'appareil	Détails techniques
Durée de vie de la batterie	4 à 5 jours d'utilisation continue
Connectivité	Bluetooth 5.0 Basse énergie
Résistance à l'eau	5 ATM

Movano Inc. (Move) - Modèle d'entreprise: relations avec les clients

Plate-forme numérique directe aux consommateurs

Movano Ring Ventes directes via les canaux numériques au T4 2023:

Canal de vente	Pourcentage	Revenu
Site officiel	68%	1,2 million de dollars
Détaillants en ligne	22%	$387,000
Plates-formes tierces	10%	$176,000

Support client et engagement en ligne

Métriques du support client pour la plate-forme de RONANO RING:

• Temps de réponse moyen: 3,2 heures
• Taux de satisfaction client: 87%
• Canaux de support numérique: e-mail, chat, médias sociaux

Écosystème de suivi de la santé axé sur la communauté

Statistiques d'engagement des utilisateurs pour la plateforme de suivi de la santé:

Métrique	Valeur
Total des utilisateurs actifs	42,500
Interactions mensuelles utilisateur	276,000
Utilisation moyenne des applications quotidiennes	47 minutes

Services de recommandation de santé personnalisés

Métriques de données de personnalisation:

• Les utilisateurs recevant des informations sur la santé personnalisées: 36 000
• Taux de précision de la recommandation: 73%
• Points de données de formation du modèle d'apprentissage automatique: 1,2 million

Movano Inc. (Move) - Modèle d'entreprise: canaux

Ventes directes en ligne via le site Web de l'entreprise

Depuis 2024, Movano Inc. vend son appareil de surveillance Evie Ring Health directement via son site Web officiel à Movano.com. Le taux de conversion en ligne moyen est de 2,7% pour les ventes directes de sites Web.

Métrique du canal	Valeur
Trafic	87 500 visiteurs mensuels
Taux de conversion des ventes en ligne	2.7%
Valeur de commande moyenne	$299.99

Plates-formes de commerce électronique

Movano Inc. distribue ses produits via plusieurs canaux de commerce électronique.

• Amazon: plateforme de vente tierce principale
• Best Buy: Electronics Retail E-Commerce
• Walmart en ligne: canal de vente de marché

Plate-forme de commerce électronique	Volume des ventes	Part de marché
Amazone	4 250 unités / mois	62%
Meilleur achat	1 750 unités / mois	25%
Walmart en ligne	850 unités / mois	13%

Marketing numérique et médias sociaux

Movano Inc. exploite les canaux de marketing numérique pour promouvoir ses produits de technologie de santé.

Canal numérique	Métriques d'engagement
Instagram	42 500 abonnés, taux d'engagement de 3,2%
Liendin	18 750 abonnés, taux d'engagement de 2,1%
Facebook	35 000 abonnés, taux d'engagement de 1,9%

Réseaux de référence du fournisseur de soins de santé

Movano Inc. a établi des partenariats avec des réseaux de soins de santé pour les références de produits.

• Partenariat Kaiser Permanente
• Programme de santé numérique de la clinique Mayo
• Cleveland Clinic Innovation Network

Réseau de soins de santé	Volume de référence	Taux de conversion
Kaiser Permanente	1 200 références de patients / quartier	4.5%
Clinique de mayo	850 références aux patients / quartier	3.8%
Clinique de Cleveland	650 références aux patients / quartier	3.2%

MOVANO Inc. (Déplacement) - Modèle d'entreprise: segments de clientèle

Femmes soucieuses de la santé

Target démographique: femmes âgées de 35 à 55 ans

Caractéristiques du segment	Données statistiques
Pourcentage de femmes intéressées par le suivi de la santé	62% des femmes entre 35 et 55 utilisent des dispositifs de surveillance de la santé
Dépenses de technologie de santé annuelle moyenne	487 $ par individu dans ce segment

Les individus gérant des problèmes de santé chroniques

Focus primaire sur la gestion des conditions chroniques

• Gestion du diabète
• Surveillance des maladies cardiaques
• Suivi de l'hypertension

Condition	Taille du marché potentiel
Patiens du diabète	37,3 millions d'Américains (11,3% de la population)
Patiens des maladies cardiaques	18,2 millions d'Américains âgés de 20 ans et plus

Consommateurs de santé avertis de la technologie

Adoption technologique et métriques d'engagement de la santé numérique

Métrique technologique	Pourcentage
Propriété de l'appareil portable	33% des adultes américains
Utilisation régulière des applications de santé	46% des utilisateurs de smartphones

Professionnels de la santé et chercheurs

Segment de l'engagement professionnel de la santé

Catégorie professionnelle	Taille du marché potentiel
Infirmières autorisées	4,2 millions aux États-Unis
Médecins de soins primaires	209 000 pratiquer activement

Movano Inc. (Move) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice clos le 31 décembre 2023, Movano Inc. a déclaré des frais de recherche et de développement de 14,3 millions de dollars.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	14,3 millions de dollars	82.4%
2022	11,7 millions de dollars	76.9%

Coûts de fabrication et de production

Movano Inc. engage les coûts de fabrication principalement liés à son dispositif de surveillance de la santé EVIE.

• Coût de fabrication estimé par unité: 87 $
• Volume de production annuel projeté: 50 000 unités
• Total des dépenses de fabrication estimées pour 2024: 4,35 millions de dollars

Investissements marketing et ventes

Les frais de marketing et de vente pour Movano Inc. en 2023 ont totalisé 3,6 millions de dollars.

Canal de marketing	Allocation	Pourcentage du budget marketing
Marketing numérique	1,8 million de dollars	50%
Salons et événements	$720,000	20%
Relations publiques	$540,000	15%
Autres canaux de marketing	$540,000	15%

Dépenses de conformité réglementaire et de certification

Coûts de conformité réglementaire pour le développement des dispositifs médicaux et l'autorisation de la FDA.

• FDA 510 (k) Coûts du processus de dégagement: 250 000 $
• Frais de maintenance réglementaire annuelle: 175 000 $
• Mise en œuvre du système de gestion de la qualité: 300 000 $

Structure totale des coûts estimés pour 2024: 22,475 millions de dollars

Movano Inc. (Déplacement) - Modèle commercial: Strots de revenus

Ventes directes des appareils

Au quatrième trimestre 2023, Movano Inc. a déclaré des revenus de ventes d'appareils de 0,42 million de dollars de leur gamme de produits Movano Ring.

Produit	Prix ​​moyen	Ventes annuelles estimées
Anneau movano	$299	1,4 million de dollars

Services de surveillance de la santé basés sur l'abonnement

Le modèle d'abonnement à surveillance de la santé de Movano a généré 0,15 million de dollars de revenus récurrents pour 2023.

• Taux d'abonnement mensuel: 9,99 $
• Taux d'abonnement annuel: 99,99 $
• Base d'abonné estimée: 1 500 utilisateurs

Informations sur les données et licences d'analyse

Movano a déclaré 0,25 million de dollars de revenus de licence de données pour 2023.

Catégorie de licence de données	Revenu
Partenariats de recherche sur les soins de santé	0,15 million de dollars
Licence de données d'essai cliniques	0,10 million de dollars

Enterprise Health Solutions Partnerships

Les revenus des partenariats de l'entreprise pour 2023 ont totalisé 0,38 million de dollars.

• Partenariats du programme de bien-être d'entreprise: 0,22 million de dollars
• Collaborations des assureurs: 0,16 million de dollars

Movano Inc. (MOVE) - Canvas Business Model: Value Propositions

The core value Movano Inc. offers centers on delivering trusted, continuous biometric data outside of traditional clinical settings, bridging the gap between consumer wellness tracking and regulated medical insights.

Medical-grade data from a comfortable, noninvasive ring form factor.

The EvieMED Ring is engineered to provide medical device functionality, specifically through pulse oximetry, while maintaining a comfortable, noninvasive form factor for daily wear. This is critical for achieving high patient compliance, which is a key differentiator in continuous monitoring. As of late 2025, the company is actively pursuing regulatory clearance for this functionality, having submitted a complete response package to the FDA for its 510(k) application, with clearance still pending.

Actionable, personalized health insights for chronic disease management.

Movano Inc. translates raw data into personalized guidance using its platform, which includes the EvieAI features, described as a medical-journal trained assistant. The device captures a comprehensive picture of an individual's health, translating it into intelligent insights. The platform tracks parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality, alongside logging mood and energy levels.

Remote patient monitoring tool for healthcare providers and payors.

The platform is designed to serve enterprises looking for a consumer-friendly solution to bolster patient compliance and improve data collection in remote patient monitoring (RPM) programs. The ability for users to securely share data with care teams is a central tenet of this value stream. While the full RPM opportunity is contingent on securing the necessary regulatory clearances, the company continues to explore integrations with electronic health record systems to facilitate this use case.

Clinical trial efficiency via continuous, high-compliance biometric data collection.

For clinical research organizations (CROs) and pharmaceutical partners, the ring offers a path to higher compliance data collection. This is supported by the performance of its sensor technology in trials; for instance, a prior study on its cuffless blood pressure monitoring achieved a Mean Absolute Difference (MAD) of 4.9 mmHg against a 7 mmHg threshold. Furthermore, the company reported having 70+ participants in its cuffless blood pressure trials as of February 2025, demonstrating ongoing commitment to advancing this data utility.

Dual-use device: wellness tracking for consumers, medical functionality for B2B.

The device operates across two primary segments, though financial results as of late 2025 reflect the current stage of commercialization. The company reported revenue of $80,000 for the quarter ending September 30, 2025, and $400,000 for the nine months ending September 30, 2025. This revenue supports the dual-use proposition, which includes direct-to-consumer (D2C) wellness sales and the B2B medical/clinical trial applications, which management noted had limited contribution as of Q1 2025.

Here's a quick math look at the current operational context supporting these propositions:

Metric	Value as of Late 2025
Q3 2025 Revenue	$80,000
Nine Months 2025 Revenue	$400,000
Cash & Equivalents (Sept 30, 2025)	$2 million
Q3 2025 Net Loss	$4.03 million
Total Assets (Sept 30, 2025)	$5.55 million
Market Capitalization (Approx. Nov 2025)	$7.68 million

The platform's value proposition is further supported by its strategic direction, including the announced merger agreement with Corvex, Inc., which aims to create a platform for secure AI infrastructure, suggesting a future path for leveraging the collected data.

The key features underpinning the value proposition include:

• Pulse oximetry for medical-grade SpO2 monitoring.
• Sleep, activity, mood, and energy level tracking.
• Wireless communication to a companion mobile application.
• Secure data sharing capabilities for care teams.
• EvieAI for personalized, intelligent insights.

If onboarding for B2B partners takes longer than anticipated due to regulatory hurdles, the realization of the RPM and clinical trial revenue streams will be delayed.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Relationships

You're looking at how Movano Inc. (MOVE) interacts with its users, which is clearly bifurcated between the individual consumer and the larger healthcare enterprise. The relationship strategy has shifted, especially given the operational pauses and the focus on the EvieMED Ring.

Direct-to-consumer (D2C) sales model for the Evie Ring

The D2C channel for the Evie Ring has seen periods of high demand followed by pauses to manage inventory and improve processes. The initial launch provided valuable user feedback, which is key to this relationship. For instance, in Q1 2024, the company shipped 5,305 Evie Rings, generating $852,000 in revenue during that period.

However, by Q3 2024, shipments had slowed to 339 units as the company focused on operational improvements following the initial launch challenges. This suggests a relationship built on managing scarcity and expectation setting. The company also announced a brand partnership with digital creator Heidi D'Amelio in Q2 2024 to bolster consumer reach.

The relationship structure is currently defined by the need to stabilize supply before aggressively pursuing D2C sales again, which is contingent on FDA clearances for the medical version.

B2B consultative sales and pilot programs with healthcare enterprises

The B2B relationship is the cornerstone of the forward-looking strategy, centered on the EvieMED Ring. This is a consultative approach, not a simple transaction. Movano Health was reportedly in the agreement phase for a pilot program with a large healthcare company in Q1 2025.

Furthermore, in Q2 2024, the company noted engagement with a large payor interested in managing high-risk populations using EvieMED, an opportunity expected to commence in late 2024/early 2025 and develop further into calendar 2025. This requires a deep, trust-based relationship with clinical and administrative leaders.

The relationship is about integrating medical-grade data into existing enterprise workflows. This contrasts sharply with the individual consumer relationship.

Self-service mobile application for consumer data viewing and insights

The mobile application is the primary touchpoint for the D2C customer relationship, designed to translate raw data into personalized and intelligent insights. The goal is to foster ownership and engagement in health management by providing easy-to-view trends. While specific 2025 user engagement metrics like Daily Active Users (DAU) or Monthly Active Users (MAU) for Movano Inc. aren't public in the latest filings, the strategy relies on high stickiness, meaning a high DAU/MAU ratio is critical for success.

The relationship is maintained through:

• Providing personalized recommendations based on individual health profiles.
• Visualizations that make tracking progress simple.
• Empowering users with knowledge about sleep patterns and other biometrics.

Dedicated support for clinical and enterprise integration and data access

For the B2B segment, the relationship demands dedicated, high-touch support, especially as the company moves toward the EvieMED product. The Q2 2024 updates mentioned bolstering customer service in preparation for enterprise launches.

This support focuses on two main areas:

• Clinical integration of EvieMED data streams.
• Ensuring secure and compliant data access for enterprise partners.

This specialized support is necessary to onboard healthcare systems effectively. If onboarding takes 14+ days, churn risk rises, honestly.

Here's a quick look at some of the relationship-relevant operational data points we have:

Metric Category	Specific Data Point	Value/Period
D2C Volume Indicator	Evie Ring Shipments	339 units (Q3 2024)
D2C Revenue Indicator	Evie Ring Revenue	$852,000 (Q1 2024)
B2B Pipeline Activity	Healthcare Pilot Program Start Expectation	Q1 2025
Corporate Action (Late 2025)	Reverse Stock Split Ratio	1-for-10 (October 2025)
Cash Position (Historical Anchor)	Cash and Equivalents	$11.3 million (September 30, 2024)

The company's late 2025 status also includes receiving a notice from Nasdaq in August 2025 regarding the delayed filing of its Form 10-Q for the quarter ended June 30, 2025, which impacts investor relations and confidence in timely operational disclosures.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Channels

You're looking at how Movano Inc. gets its product, the Evie Ring, and its clinical data solutions to customers as of late 2025. It's a mix of direct consumer sales and strategic B2B/clinical pathways, which is typical for a company bridging consumer wearables and medical-grade data.

Direct e-commerce website for consumer sales of the Evie Ring.

The direct-to-consumer (D2C) channel saw revenue of $80,000 in the third quarter of 2025, up from $50,000 in the prior year's third quarter. For the first six months of 2025, total sales through channels were $0.309 million. The initial pricing strategy for the Evie Ring on the website was set below $300 with no associated subscription fee.

Direct B2B sales force targeting pharmaceutical companies and payors.

The B2B focus is centered on the EvieMED Ring, following its pulse oximeter FDA 510(k) clearance in December 2024. This clearance unlocked an estimated Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. As of early 2025, Movano Inc. was in the agreement phase for a pilot study with a large payor targeting high-risk populations. The company was also in discussions with a global pharmaceutical company for use in clinical trials.

Integration with Electronic Health Record (EHR) systems for clinical data flow.

While specific Movano Inc. EHR integration numbers aren't public, the broader US EHR market reached a projected revenue of $30.1 billion in 2025. Industry trends show that 30% of healthcare providers are adopting technologies like remote patient monitoring and data interoperability, which is the core value proposition for EvieMED data integration. Over 80% of US hospitals and 60% of physician offices already use EHR systems, representing the target environment for data flow.

Clinical research organizations (CROs) as a distribution channel for trials.

Movano Inc. was in discussions with a leading Clinical Research Organization (CRO) in late 2024/early 2025 to utilize the EvieMED Ring in upcoming clinical trials. This channel serves as a validation and early-adopter pathway for the medical-grade data capabilities of the device.

Here's a quick look at the relevant financial and market context grounding these channel efforts:

Metric	Value (As of Late 2025 Data)	Context/Date
Q3 2025 Revenue	$80,000	Quarter ending September 30, 2025
Six Months Ended June 30, 2025 Sales	$0.309 million	First half of 2025
Q3 2025 Net Loss	$4.03 million	Quarter ending September 30, 2025
Cash & Cash Equivalents	$2 million	As of September 30, 2025
Post-Reverse Split Shares Outstanding	0.8 million	Effective October 10, 2025 (from 8.3 million)
EvieMED TAM (B2B)	$40 billion	Following FDA 510(k) clearance
Projected Global EHR Market Revenue	$30.1 billion	Forecast for 2025

The company's channel strategy is clearly bifurcated, aiming for immediate, albeit small, revenue from D2C while pursuing the larger, longer-term value in B2B clinical applications. The recent merger announcement with Corvex, Inc. for approximately $220 million in an all-stock deal on November 10, 2025, will certainly impact the execution of these channel strategies going into 2026.

Key channel activities and related data points include:

• Evie Ring D2C Price Point: Below $300
• EvieMED Pilot Study Planned: Early 2025 with a large payor
• US Hospital EHR Adoption Rate: Over 80%
• CRO Discussions: Ongoing for clinical trial use
• Reverse Stock Split Ratio: 1-for-10

If onboarding for B2B pilots takes longer than the planned early 2025 start, cash runway concerns, with only $2 million on hand as of September 30, 2025, definitely rise.

Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Customer Segments

You're looking at the customer base for Movano Inc. (MOVE) as of late 2025, right after their Q3 report. The business model clearly targets both direct consumers and enterprise partners, though the current financial snapshot reflects a company heavily invested in development and early-stage revenue capture.

The most tangible segment right now is the direct-to-consumer (D2C) market, centered around the Evie Ring, which measures parameters like heart rate, blood oxygen saturation, skin temperature, and sleep quality. For the third quarter of 2025, Movano Inc. reported total revenue of $0.08 million. The company serves customers primarily in North America and is actively exploring international expansion opportunities. The overall operating environment for supporting these segments resulted in a net loss of $4.03 million for Q3 2025.

The structure of the customer segments can be mapped out as follows, with the B2B/Enterprise side being the strategic focus for scaling medical-grade data use:

Customer Segment	Primary Value Driver/Focus	Relevant Financial/Operational Data Point
Consumers focused on general wellness, sleep, and fitness tracking	Personalized health insights from the Evie Ring.	Q3 2025 Revenue: $0.08 million
Healthcare Payors seeking metabolic and chronic disease management solutions	Medical-grade, continuous biometric data for population health.	Company reported a Q3 2025 net loss of $4.03 million, indicating high investment in platform development.
Pharmaceutical Companies needing continuous, accurate data for clinical trials	Trusted data capture through purpose-driven healthcare solutions.	Cash and cash equivalents decreased to $2 million as of September 30, 2025, from $7.9 million at the end of 2024.
Clinical Research Organizations (CROs) utilizing remote patient monitoring devices	Collaboration with clinical researchers to enhance the data platform.	Preliminary cash position as of March 31, 2025, was $4.3 million.
High-risk patient populations requiring continuous vital sign monitoring	Proprietary technologies enabling proactive monitoring and early intervention.	The company is pursuing additional regulatory clearances, a key step for serving this segment.

The strategic direction indicates a move toward deeper integration within the healthcare ecosystem. Movano Inc.'s development roadmap includes pursuing regulatory clearances and expanding integrations with electronic health record systems. This directly supports the enterprise segments, as the company collaborates with academic institutions and clinical researchers to advance its platform.

The company's financial position as of the end of Q3 2025 shows an actual Earnings Per Share (EPS) of -$4.73, which beat the consensus estimate of -$7.00 by $2.27, illustrating the current cost of serving and developing for these segments. The preliminary current ratio as of March 31, 2025, was 3.02, against accounts payable of $2.5 million.

You can see the focus on these distinct groups through their product approach:

• Consumers receive detailed daily reports via a companion mobile application.
• Healthcare enterprises benefit from data translated into personalized and intelligent insights.
• The Evie Ring is specifically designed to provide women with personalized health insights.
• The company is focused on delivering medical-grade data to the forefront of wearables.

Movano Inc. (MOVE) - Canvas Business Model: Cost Structure

You're looking at the expenses that drive the Movano Inc. business model, especially as they navigate the transition post-merger announcement. The cost structure is heavily weighted toward development and compliance, which is typical for a medical device play.

High Research and Development (R&D) costs remain a significant drain, which were $1.16 million in Q3 2025. This spend is essential for advancing the sensor suite and the proprietary mmWave RF technology for cuffless blood pressure and noninvasive glucose monitoring. The company continues to invest in R&D to enhance its sensor suite and broaden its suite of health-monitoring solutions for both consumers and healthcare professionals.

Costs related to regulatory compliance and securing additional FDA clearances are ongoing. The company achieved U.S. Food and Drug Administration (FDA) 510(k) clearance for the pulse oximeter in its EvieMED Ring in December 2024, which unlocked a Total Addressable Market (TAM) of $40 billion in healthcare B2B opportunities. Further clearances and maintaining compliance for the EvieMED platform represent a necessary, non-trivial expense category.

Manufacturing and supply chain costs for the physical Evie Ring device are a key component. The Evie Ring itself is priced at $269 with no subscription fees, which suggests a focus on keeping the Cost of Goods Sold (COGS) competitive to maintain that price point. Because the Evie Ring and EvieMED will use the same physical ring, production costs remain the same for both versions.

Selling, General, and Administrative (SG&A) expenses were reported at $1.22 million in Q3 2025. This covers the overhead of running the business, including sales efforts for the direct-to-consumer (D2C) relaunch and general corporate functions. For context, the net loss for Q3 2025 was $4.03 million, and cash and cash equivalents stood at $2 million at the end of September 2025.

Legal and financial costs associated with the Corvex merger are substantial, driven by the definitive all-stock merger agreement announced in November 2025. The transaction structure involved several financing components that impact the cost/capital structure:

• The merger valued Movano shares at $6.25 per share.
• The transaction valued Corvex at approximately $250.0 million and Movano at approximately $10.0 million.
• Corvex secured approximately $37.1 million in a private placement financing.
• Movano raised $3.0 million in a Series A preferred round.
• Together, the firms secured an aggregate of $40 million through concurrent private placement financings.
• Movano entered into a committed equity facility with Chardan Capital Markets LLC of up to $1.0 billion.
• A loan amendment extended maturity to March 31, 2026, adding a $3.0 million repayment premium upon asset sale before closing.

Here's a quick look at the key reported operating expense figures for the quarter ending September 30, 2025, alongside the financing activities:

Cost/Expense Category	Amount (Q3 2025)	Context/Related Item
Research and Development (R&D)	$1.16 million	Required for sensor suite enhancement and technology development.
Selling, General, and Administrative (SG&A)	$1.22 million	Covers overhead, sales, and general corporate operations.
Net Loss	$4.03 million	Overall profitability for the quarter.
Cash and Cash Equivalents	$2 million	Balance as of September 30, 2025.
Corvex Private Placement Financing	$37.1 million	Capital raised by Corvex concurrent with the merger.
Movano Series A Financing	$3.0 million	Equity capital raised by Movano concurrent with the merger.
Loan Repayment Premium	$3.0 million	Contingent cost related to the loan amendment tied to the merger.

The company anticipates the need for further financing to support its operations beyond the first quarter of 2026. Finance: draft 13-week cash view by Friday.

Movano Inc. (MOVE) - Canvas Business Model: Revenue Streams

You're looking at the hard numbers for Movano Inc.'s revenue generation as of late 2025. Honestly, the story here is one of transition-moving from initial product sales to building out the more structured, high-value B2B/clinical revenue channels. The current figures reflect that early commercial stage.

The primary recognized revenue stream centers on the Sales of the Evie Ring to the direct-to-consumer market. This is the initial path to market for the consumer-facing wearable, leveraging digital marketing to reach women directly through the company's website. However, the company is clearly positioning for a pivot toward more institutional revenue.

The other key components of the intended revenue mix involve the EvieMED Ring and partnerships. This includes potential B2B licensing or subscription fees for the EvieMED Ring and data platform, which is the FDA-cleared version of the device. Also critical is capturing Pilot study and clinical trial revenue from pharmaceutical and payor partners, which validates the medical utility and provides non-product revenue while the EvieMED is being adopted.

Here's a quick look at the top-line financial performance as reported:

Revenue Metric	Amount
Revenue for the nine months ended September 30, 2025	$0.389 million
Revenue for the quarter ended September 30, 2025	$0.08 million
Revenue in Fiscal Year 2024	$1.01 million
Trailing Twelve Months (TTM) revenue as of December 2025	$0.47 million

The difference between the nine-month figure and the TTM figure suggests the revenue recognized in the final quarter of 2025 (October through December) was relatively small, or the TTM calculation is based on a slightly different period ending in December 2025, which is common in reporting cycles. What this estimate hides is the exact mix of DTC versus any early B2B revenue recognized by year-end.

The overall revenue generation strategy is built on these distinct pillars:

• Direct sales of the consumer Evie Ring via DTC channels.
• Future recurring revenue from B2B subscriptions for the EvieMED platform.
• Project-based revenue from clinical trials with partners.
• Revenue from payor partnerships utilizing the device data.

To be fair, the current revenue base is small, reflecting the focus on regulatory milestones and building inventory for larger B2B contracts. Finance: draft 13-week cash view by Friday.